

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7835867

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CELL THERAPY AND TECHNOLOGY, S.A. DE C.V.	06/08/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	EXCALIBUR PHARMACEUTICALS, INC.
<b>Street Address:</b>	9 SNIFFEN COURT
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10016
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17351151
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)646-8646
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6176468000
<b>Email:</b>	lili.koen@wolfgreenfield.com
<b>Correspondent Name:</b>	DANIELLE C. SAMBLANET
<b>Address Line 1:</b>	WOLF, GREENFIELD & SACKS, P.C.
<b>Address Line 2:</b>	600 ATLANTIC AVENUE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210
<b>ATTORNEY DOCKET NUMBER:</b>	C1603.70000US05
<b>NAME OF SUBMITTER:</b>	DANIELLE C. SAMBLANET
<b>SIGNATURE:</b>	/Danielle C. Samblanet/
<b>DATE SIGNED:</b>	03/09/2023
<b>Total Attachments: 23</b>	
source=C160370000US05-ASI-DCS#page1.tif	
source=C160370000US05-ASI-DCS#page2.tif	
source=C160370000US05-ASI-DCS#page3.tif	
source=C160370000US05-ASI-DCS#page4.tif	
source=C160370000US05-ASI-DCS#page5.tif	

source=C160370000US05-ASI-DCS#page6.tif  
source=C160370000US05-ASI-DCS#page7.tif  
source=C160370000US05-ASI-DCS#page8.tif  
source=C160370000US05-ASI-DCS#page9.tif  
source=C160370000US05-ASI-DCS#page10.tif  
source=C160370000US05-ASI-DCS#page11.tif  
source=C160370000US05-ASI-DCS#page12.tif  
source=C160370000US05-ASI-DCS#page13.tif  
source=C160370000US05-ASI-DCS#page14.tif  
source=C160370000US05-ASI-DCS#page15.tif  
source=C160370000US05-ASI-DCS#page16.tif  
source=C160370000US05-ASI-DCS#page17.tif  
source=C160370000US05-ASI-DCS#page18.tif  
source=C160370000US05-ASI-DCS#page19.tif  
source=C160370000US05-ASI-DCS#page20.tif  
source=C160370000US05-ASI-DCS#page21.tif  
source=C160370000US05-ASI-DCS#page22.tif  
source=C160370000US05-ASI-DCS#page23.tif

## EXHIBIT B-2: FORM OF PATENT ASSIGNMENT

### ASSIGNMENT

THIS ASSIGNMENT, dated as of June [●], 2020, is made by Cell Therapy Technology S.A. de C.V., a corporation organized under the laws of Mexico (“ASSIGNOR”), in favor of Excalibur Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, USA (“ASSIGNEE”).

WHEREAS, ASSIGNOR has right, title, and interest in, to, and under the Patents and Patent Applications referred to in **Schedule 1** to Exhibit B-2: Form of Patent hereto (“ASSIGNED IP”);

WHEREAS ASSIGNEE is desirous of obtaining ASSIGNOR’s entire right, title, and interest in, to and under the ASSIGNED IP;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby:

1. Assigns and transfers to ASSIGNEE, its successors, assigns, and legal representatives, the entire right, title, and interest for the United States and all foreign countries, in and to any and all inventions and designs which are disclosed in the ASSIGNED IP and all corresponding provisional, non-provisional, divisional, continuing, substitute, renewal, reissue, and all other patent applications, utility models, industrial designs, or similar intellectual property rights which have been or shall be filed in the United States, internationally, and in any foreign country or regional patent office, including, but not limited to, China, Europe, Japan, and Korea, on any of the inventions; and in and to all original and reissued patents which have been or shall be issued in the United States or any other jurisdiction on the inventions, including the right to apply for patent rights in any foreign country and regional patent office and all rights to priority, including the right to claim priority in any foreign country or regional patent office, including, but not limited to, China, Europe, Japan, and Korea, as well as the right to sue in its own name and recover damages for past infringement of any United States Letters Patent or foreign patent, including a reasonable royalty relating to provisional rights such as under 35 U.S.C. § 154(d) that have attached to any published United States patent application, on the inventions and designs;

2. Agrees that ASSIGNEE may apply for and receive Letters Patent and utility model and industrial design registrations for the inventions and designs in its own name; and when requested, without charge to but at the expense of the ASSIGNEE, agree to carry out in good faith the intent and purpose of this ASSIGNMENT, by executing all non-provisional, divisional, continuing, substitute, renewal, reissue, and all other patent, utility model, and industrial design applications on any and all the inventions and designs, by executing all rightful oaths, assignments, powers of attorney, and other papers, by communicating to the ASSIGNEE all facts known to ASSIGNOR relating to the inventions and designs and the history thereof, and generally by doing everything reasonably possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper protection for the inventions and designs and for vesting title to the inventions and designs and all applications for patents and all patents on the inventions and designs, in the ASSIGNEE;

3. Requests the Director of the United States Patent and Trademark Office and foreign patent authorities to issue the Letters Patent or other intellectual property rights, including foreign patents, to ASSIGNEE;


4. Covenant with ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by ASSIGNOR, and that full right to convey the same as herein expressed is possessed by ASSIGNOR; and

5. Appoint ASSIGNEE, through its designee, ASSIGNOR's attorney-in-fact to execute, in ASSIGNOR's name and on ASSIGNOR's behalf, any and all documents required to effectuate this ASSIGNMENT, specifically including, but not limited to, those documents specified above and any necessary corrective assignments.

This instrument is executed under seal and signed under the pains and penalties of perjury under the laws of the United States of America.

On behalf of ASSIGNOR Cell Therapy Technology S.A. de C.V.


June 8<sup>th</sup>, 2020  
Date

  
Signature

Name: José Agustín Rogelio Magaña-Castro

Title: CEO


Witness:  
June 8<sup>th</sup>, 2020  
Date

  
Signature

Name: Celso Peña Santiago

Address: Carretera Toluca e Cuernavaca  
7144-7

Witness:  
June 18<sup>th</sup>, 2020  
Date

  
Signature

Name: Milom Hernández García

Address: Calle de las Flores 128  
Cu. Ejecutivos, Anáhuac Edm

On behalf of ASSIGNOR Cell Therapy Technology S.A. de C.V.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

Name: \_\_\_\_\_

Address: \_\_\_\_\_  
\_\_\_\_\_

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

Name: \_\_\_\_\_

Address: \_\_\_\_\_  
\_\_\_\_\_

Accepted and agreed to on behalf of ASSIGNEE Excalibur Pharmaceuticals, Inc.

June 16, 2020  
Date


  
Signature

Name: Christopher Martell

Title: President

Witness:

6/16/2020  
Date


  
Signature

Name: Margy Nederlander

Address: 117 Duck Pond Lane  
SH NY 11968

Witness:

June 16, 2020  
Date

  
Signature

Name: Arianna Martell

Address: 9 Shiffen Court  
NY NY 10016

Accepted and agreed to on behalf of ASSIGNEE Excalibur Pharmaceuticals, Inc.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

Name: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

Name: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_



**SCHEDULE 1  
TO EXHIBIT B-2: FORM OF PATENT  
ASSIGNMENT**

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Mexico	324,055	7/19/2011	Procedure for the manufacture of a pharmaceutical composition in the form of an extended- release tablet containing Pirfenidone and its application in the regression of chronic renal failure, breast capsular contracture and human liver fibrosis (KitosCell LP)	Active	324055	10/01/2014	Cell Therapy and Technology S.A. de C. V.
Argentina	P 12 01 02578 (AR087205)	07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged release tablets containing pirfenidone and its application in the regression of chronic renal failure, mammary capsular contracture and human liver fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Australia	2012284627	07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic renal failure, breast capsular contracture and human liver fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Bolivia	SP-0230-2012	07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic renal failure, breast capsular contracture and human liver fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Colombia	14008053 33,599 (CO6930357)	07/13/2012	Pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and manufacturing procedure.	Active	33599	11/04/2016	Cell Therapy and Technology S.A. de C. V.
Canada	2842654	07/13/2012		Active			Cell Therapy and Technology S.A. de C. V.
European Community	15161929	07/13/2012		Germany (DE15161929), Austria, Belgium, Bulgaria, Cyprus (CY1119886),	2,907,506	11/15/2017	Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)	
				Croatia (HR20180183), Denmark (DK2907506), Slovakia, Slovenia (SI2907506), Spain (ES2550227), Estonia, Finland, France, Greece, Hungary (HU036511), Ireland, Italy, Latvia, Lithuania (LT2907506), Luxembourg, Malta, Netherlands, Poland (PL2907506), Portugal (PT2907506), Great Britain, Czech Rep., Romania, Sweden, Albania, Macedonia, Norway, Switzerland, Lichtenstein, Turkey (TR201511515), Monaco, Iceland, Serbia (RS56858), San Marino / Rights in force <b>*validated:</b> Belgium, Estonia, Spain, Finland, Croatia, Netherlands, Romania, Slovakia, and Turkey				
Europe (Div 1)	EP20120766487 15 161 929.3	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular	Granted	EP 2 907 506 B1	11/15/2017	Cell Therapy and Technology S.A. de C. V.	

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			contracture and hepatic fibrosis in humans				
Chile	131-2014	07/13/2012	Pharmaceutical composition in the form of prolonged-release tablets comprising pirfenidone; use in the treatment or regression of chronic renal failure, breast capsular contracture and liver fibrosis.	Active	58488	01/29/2020	Cell Therapy and Technology S.A. de C. V.
South Korea	10-2014-7002065	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans.	Active	10-1632332		Cell Therapy and Technology S.A. de C. V.
South Korea (Div 1)	10-2016-7015898	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans.	Pending			Cell Therapy and Technology S.A. de C. V.
China	201280045648.X	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans.	Abandoned – Dec. 30, 2019			Cell Therapy and Technology S.A. de C. V.
Costa Rica	2014-0019	07/13/2012	Process for the manufacture of a pharmaceutical in the form of prolonged-release tablets comprising pirfenidone.	Active	3831	11/18/2019	Cell Therapy and Technology S.A. de C. V.
United States	14/233,600; US 2014-0296300	07/13/2012	A Pharmaceutical composition containing pirfenidone in sustained-release tablet form	Active	9,408,836	08-09-2016	Cell Therapy and Technology S.A. de C. V.
United States (Div. 1)	15/177,760; US 2016-0287567	06/09/2016	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis	Active	9,962,374	05-08-2018	Cell Therapy and Technology S.A. de C. V.
United States (Div. 2)	15/831,650; US 2018-0092893	12/05/2017	Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form	Active	10,383,862	08-20-2019	Cell Therapy and Technology S.A. de C. V.
United States (Div. 3)	16/460,407; US-2019-0358213	07/2/2019	Methods of using a pharmaceutical composition	Pending			Cell Therapy and

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			containing pirfenidone in sustained-release tablet form				Technology S.A. de C. V.
United States (Div. 4)	16/544,643; US-2020-0038386	8/19/2019	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis	Pending			Cell Therapy and Technology S.A. de C. V.
Hong Kong	HK1208172	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans.	Active	HK1208172	03/08/2018	Cell Therapy and Technology S.A. de C. V.
Ecuador	SP-14-13160	07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic renal failure, mammary capsular contracture and human liver fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Iraq	2012/204	07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and its application in the regression of chronic renal failure, breast capsular contracture and human liver fibrosis.	Active	4,039	10/14/2014	Cell Therapy and Technology S.A. de C. V.
Japan	2014-521581	07/13/2012	Process for the preparation of pharmaceutical compositions containing pirfenidone in the form of sustained release tablets and its application in the regression of human chronic renal failure, breast capsule contracture and liver fibrosis	Active	6,034,380	11/04/2016	Cell Therapy and Technology S.A. de C. V.
Egypt	PCT 69/2014	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regress	Pending			Cell Therapy and Technology S.A. de C. V.
Macedonia	MK7409	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans	Pending			Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Nigeria	PCT/MX2012/000067 NG / C / 2014/009 1/18/53123	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis.	Granted	NG / C / 2014/009	01/17/2014	Cell Therapy and Technology S.A. de C. V.
Jamaica	1/18/53123	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Panama	89,796	07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic kidney failure, breast capsular contracture and human liver fibrosis.	Active	89796-01	01/27/2014	Cell Therapy and Technology S.A. de C. V.
Jordan	186/2012	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Peru	000097-2014 9223 (PE16842014)	07/13/2012	Prolonged-release tablets comprising pirfenidone, and procedure for its manufacture.	Active	9223	09/25/2018	Cell Therapy and Technology S.A. de C. V.
India	415 / DELNP / 2014	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
South Africa	2014-00386	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis	Active	2014/00386	04/29/2015	Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Indonesia	P00201400259	01/17/2014	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis	Pending			Cell Therapy and Technology S.A. de C. V.
Ukraine	201401623	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis	Active	114,181	10/05/2017	Cell Therapy and Technology S.A. de C. V.
Paraguay	33418/2012	07/13/2012 07/18/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic kidney failure, breast capsular contracture and human liver fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
Brazil	BR112014001297	01/17/2014 07/12/2012	Procedure for the manufacture of a pharmaceutical composition in the form of long-acting pirfenidone-containing tablets and their application in the regression of chronic renal failure, human breast capsular contracture and hepatic fibrosis	Pending  Official notification by the Patent / Rights Office is required			Cell Therapy and Technology S.A. de C. V.
Dominican Republic	P2014-011	01/20/2014 07/13/2012	Pharmaceutical composition in the form of prolonged-release tablets comprising pirfenidone; use in the treatment or regression of chronic kidney failure, breast capsular contracture and liver fibrosis	Pending			Cell Therapy and Technology S.A. de C. V.
Russia	2014101231 (RU2682177)	07/13/2012	A process for the preparation of a pharmaceutical composition in the form of extended release tablets containing pirfenidone and their use for the regression of chronic renal failure, and hepatic capsular fibrosis in humans	Active	2682177	03/15/2019	Cell Therapy and Technology S.A. de C. V.
Thailand	14010000282	07/13/2012	Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis	Pending			Cell Therapy and Technology S.A. de C. V.
Uruguay	34190	07/09/2012	Procedure for the manufacture of a pharmaceutical	Pending			Cell Therapy and

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic kidney failure, breast capsular contracture and human liver fibrosis.				Technology S.A. de C. V.
Venezuela	2012-000891	07/17/2012 07/13/2012	Procedure for the manufacture of a pharmaceutical composition in the form of prolonged-release tablets containing pirfenidone and its application in the regression of chronic kidney failure, breast capsular contracture and human liver fibrosis.	Pending			Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2012/000067 (WO 2013/012307)	07/13/2012	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans	Published			Cell Therapy and Technology S.A. de C. V.
Mexico	MX/a/2016/014775 (MX364040)	11/11/2016	Pharmaceutical Use of a Composition Containing Prolonged Release Pirfenidone (PFD-LP) for the Reversal and Treatment of Human Steatohepatitis (NAFLD / NASH)	Active	MX364040	03/21/2019	Cell Therapy and Technology S.A. de C. V.
Argentina	P170103142	10/11/2017 11/09/2017	Pharmaceutical use of a prolonged release composition (PFD-LP) for the reversal and treatment of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Australia	2017358367	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Brazil	BR112019 009400-8	11/09/2017 05/09/2019	Pharmaceutical use of a prolonged release composition (PFD-LP) for the reversal and treatment of human steatohepatitis (NALD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Canada	CA3043300)	11/09/2017	Pharmaceutical use of a prolonged release composition (PFD-LP) for the reversal and treatment of human steatohepatitis (NALD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Chile	01280-2019	11/09/2017 05/09/2019	Pharmaceutical use of a prolonged-release pirfenidone containing composition	Pending			Cell Therapy and

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			(PFDLP) For the reversal and treatment of human steatohepatitis (NAFLD / NASH)				Technology S.A. de C. V.
China	CN110248646	11/09/2017	Slow releasing composition comprising pirfenidone is used to treat and reverse the medicinal usage of people's steatohepatitis (NAFLD/NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Colombia	NC2019 / 0004799	11/09/2017 05/09/2019	Pharmaceutical use of a prolonged-release pirfenidone containing composition (PFDLP) for the reversal and treatment of human steatohepatitis (NAFLD / NASH).	Pending			Cell Therapy and Technology S.A. de C. V.
European Community (Current Rights)	17 840 578.3 (EP3539537)	11/09/2017		Pending: Albania, Germany, Austria, Belgium, Bulgaria, Cyprus, Croatia, Denmark, Slovakia, Slovenia, Spain, Estonia, Finland, France, Greece, Hungary, Ireland, Iceland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Monaco, Macedonia, Netherlands, Norway, Poland, Portugal, Great Britain, Czech Rep., Romania, Serbia, San Marino, Turkey, Sweden, Switzerland			Cell Therapy and Technology S.A. de C. V.
South Korea	10-2019-7014274 (KR20190084056)	11/09/2017 5/17/2019	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)	Pending			Cell Therapy and Technology S.A. de C. V.



Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Ecuador	SENADI-2019-31851	11/09/2017 08/05/2019	Pharmaceutical use of a prolonged-release pirfenidone containing composition (PFDLP) for the reversal and treatment of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Egypt	PCT 720/2019	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
United States	16/348,189; US 2019/0262325	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
India	201917019019	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Indonesia	P00201904771	11/09/2017	Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans.	Abandoned			
Japan	JP2019535822 519168561	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Nigeria	NG/PT/C/2019/370 0	10/05/2019	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Norway	17 840 578.3 (EP3539537)	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Pakistan	579/2017	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)	Pending			Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Paraguay	85588/2017	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Israel	IL266519	11/09/2017	Pharmaceutical use of a composition containing pirfenidone of extended-release for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Abandoned			Cell Therapy and Technology S.A. de C. V.
Peru	946-2019 (PE20191149)	11/09/2017 05/17/2019	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Russia	2019116422	11/09/2017	Pharmaceutical use of a composition containing pirfenidone of extended-release for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
South Africa	2019/03012	11/09/2017 05/14/2019	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Switzerland	17 840 578.3 (EP3539537)	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Turkey	17 840 578.3 (EP3539537)	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Uruguay	37478	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Pending			Cell Therapy and Technology S.A. de C. V.
Venezuela	2017-000431	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD / NASH)	Abandoned			Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2017/0001 29 (WO 2018/088886)	11/09/2017	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of	Published			Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			human steatohepatitis (NAFLD / NASH)				
Mexico	Mx /a / 2007/009796 302,983	08/14/2007	Gel containing Pirfenidone (KitosCell Gel PFD) (Topical antifibrotic agent, to prevent the formation of keloid and hypertrophic scars	Abandoned	302,983	09/03/2012	Cell Therapy and Technology S.A. de C. V.
Brazil	BRPI0815203	08/14/2008	Gel containing Pirfenidone	Pending			Cell Therapy and Technology S.A. de C. V.
Canada	2,696,335	08/14/2008	Gel containing Pirfenidone	Active	2,696,335	03/14/2014	Cell Therapy and Technology S.A. de C. V.
Chile	49,911	08/14/2008	Pharmaceutical gel composition comprising: 8% pirfenidone, 0.5% carbopol, 20% Nmethylpyrrolidone, 11.5% macroglycerol hydroxystearate, 0.5% diazolidinyurea and Iodopropinylbutylcarbamate, 0.5% triethanolamine and the rest of purified water; fabrication process; and use to prevent and treat fibrotic lesions.	Abandoned	49,911	06/06/2014	Cell Therapy and Technology S.A. de C. V.
Colombia	T0015040 001-82,582 (CO6180448A2)	08/14/2008	Gel containing Pirfenidone	Active	2,582	06/24/2013	Cell Therapy and Technology S.A. de C. V.
European Community; Awarded - Pending validation of European countries where protection is requested	EP08827482.4A	08/14/2008	Gel containing pirfenidone	Active: Germany, Austria, Belgium, Bulgaria, Cyprus, Croatia, Denmark, Slovakia, Slovenia, Spain, Estonia, Finland, France, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Great Britain Czech Rep., Romania, Sweden,	EP2177220	05/29/2019	Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
				Norway, Switzerland, Liechtenstein, Turkey, Monaco			
South Korea	10-2014-7002065 10-1235968	08/14/2008	Gel containing pirfenidone	Active			Cell Therapy and Technology S.A. de C. V.
United States	12/673,304; US 2011/0224265	08/14/2008	Gel containing pirfenidone	Active	8,492,412	07/23/2013	Cell Therapy and Technology S.A. de C. V.
United States (Div. 1)	15/435,494; US 2017-0216268	02/17/2017	Gel containing pirfenidone	Active	10,376,500	08-13-2019	Cell Therapy and Technology S.A. de C. V.
United States (Div. 2)	15/831,650; US 2018-0092893	12/05/2017	Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form	Active	10,383,862; see family 1	08-20-2019	Cell Therapy and Technology S.A. de C. V.
United States	13/893,626; US 2013-0245073	05/13/2013	Gel containing pirfenidone	Abandoned (4/3/17)			Cell Therapy and Technology S.A. de C. V.
United States	16/450,150; US 2020-0016138	06/24/2019	Gel containing pirfenidone	Pending			Cell Therapy and Technology S.A. de C. V.
Japan	JP 2010520954A	08/14/2008	Gel containing pirfenidone	Active	5,542,053	07/09/2014	Cell Therapy and Technology S.A. de C. V.
India	270193 (923/DELNP/2010)	08/14/2008	Gel containing pirfenidone	Active	270193	11/30/2015	Cell Therapy and Technology S.A. de C. V.
South Africa	2010/00918	08/14/2008	Gel containing Pirfenidone	Active	2010/00918	04/28/2011	Cell Therapy and Technology S.A. de C. V.
China	200880103142.3	08/14/2008	Gel containing Pirfenidone	Abandoned			Cell Therapy and Technology S.A. de C. V.
China (Div 1)	201510091398.9	08/14/2008	Gel containing Pirfenidone	Abandoned			Cell Therapy and Technology S.A. de C. V.
Ecuador	SP-2010-9960	08/14/2008	Gel containing Pirfenidone	Abandoned			Cell Therapy and Technology S.A. de C. V.
Hong Kong	15112082.7	08/14/2008	Gel containing Pirfenidone	Pending			Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Hong Kong	HK20100110152	08/14/2008	Gel containing Pirfenidone	Pending			Cell Therapy and Technology S.A. de C. V.
Singapore	<u>SG183732 A1</u>	08/14/2008	Gel containing Pirfenidone	Abandoned			Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2008/000107 (WO 2009/022899)	08/14/2008	Gel containing Pirfenidone	Published			Cell Therapy and Technology S.A. de C. V.
Mexico	Mx /a/ 2012/003694  346,763	03/28/2012	Semisolid topical composition containing Pirfenidone and Diallyl Modified Disulfide Oxide (O-DDM) to eliminate or prevent acne (ZaxCell)	Active	346,763	03/31/2017	Cell Therapy and Technology S.A. de C. V.
United States	15/098,970; US 2016-0228424	04/14/2016	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Active	9,949,959	04-24-2018	Cell Therapy and Technology S.A. de C. V.
United States (Div. I)	15/920,822; US 2018-0214434	03/14/2018	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
United States	14/388,447; US 2015-148382	02/05/2015	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
United States	16/534,980	08/7/19	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Pending			Cell Therapy and Technology S.A. de C. V.
Canada	2,868,729	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Pending			Cell Therapy and Technology S.A. de C. V.
Argentina	ARP130100926A AR090457	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Australia	AU2013240709	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Brazil	BR112014023836	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide	Abandoned			Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			oxide (ODD-M) for eliminating or preventing acne.				
Chile	CL2014002591	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
China	CN104334171	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Colombia	CO7071140	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Cuba	CU20140114	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Dominican Republic	DOP2014000218	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Eurasian Patent Org.	EA201401031	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Europe	EP2832354	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Indonesia	ID201601496	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Israel	IL234816	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
India	IN08067DN2014	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Japan	JP2015513359	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
South Korea	KR20140146144	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Morocco	MA20150062	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Philippines	PH2014502154	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Singapore	SG11201406035V	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Tunisia	TN2014000396	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
Uruguay	UY34700	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Abandoned			Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2013/000027 (WO 2013/147577)	02/27/2013	Semisolid topical composition containing pirfenidone and modified diallyl disulphide oxide (ODD-M) for eliminating or preventing acne.	Published			Cell Therapy and Technology S.A. de C. V.
Mexico	MX/ a/ 2017/010486	08/15/2017	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage (KitosCell Q)	Active	MX366086	06/27/2019	Cell Therapy and Technology S.A. de C. V.
Australia	2018317188	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			
Argentina	P180102342 (AR112474)	08/10/2018	Semisolid topical Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Abandoned			Cell Therapy and Technology S.A. de C. V.
Canada	CA3072855	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
China	P20H49301AJ	03/13/2020	Topical semisolid composition containing an antimicrobial	Pending			Cell Therapy and

Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
			agent and pirfenidone for the treatment of chronic skin damage				Technology S.A. de C. V.
Europe	EP 18839550.3	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
India	202017005872	02/11/2020	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
Japan	2020-508593	02/14/2020	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
New Zealand	762547	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
South Korea	10-2020-7007458	02/14/2020	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
Russia	2020110783	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
Singapore	11202002214Q	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
United States	16/638621	02/12/20	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Pending			Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2018/000071 (WO 2019/035705)	08/10/2018	Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage	Published			Cell Therapy and Technology S.A. de C. V.
Mexico	MX/a/2018/010528	08/5/2017 08/31/2018	Semisolid oil- based pharmaceutical composition containing Pirfenidone for application in tissue repair (KitoCream)	Active	368750	10/15/2019	Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2019/000093 (WO 2020/046102)	08/23/2019	Semisolid oil- based pharmaceutical composition containing Pirfenidone for application in tissue repair	Published			Cell Therapy and Technology S.A. de C. V.



Country	Application/Publication No.	Filing Date	Title	Status	Patent No.	Issue Date	Owner/Assignee (Purported)
Mexico	MX2007006349	05/29/2007	New synthesis process for obtaining 5-methyl-1-phenyl-2-(1H)-pyridone, composition and use thereof.	Active	317943	02/10/2014	Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2008/000069 (WO 2008/147170)	05/29/2008	New process of synthesis for obtaining 5-methyl-1-phenyl-2(ih)-pyridone, composition and use of the same	Published			Cell Therapy and Technology S.A. de C. V.
Mexico	MX2007006347	05/29/2007	Use of 5-methyl-1-phenyl-2-(1h)-pyridone for the prevention of hypertrophic scars, and composition containing the same. (Breast Contractures)	Active	312761	08/29/2013	Cell Therapy and Technology S.A. de C. V.
PCT	PCT/MX2008/000067 (WO 2008/147168)	05/29/2008	Use of 5-methyl-1-phenyl-2-(1h)-pyridone for the prevention of hypertrophic scars, and composition containing the same. (Breast Contractures)	Published			Cell Therapy and Technology S.A. de C. V.
Mexico	MX2007006348	05/29/2007	Microemulsion containing pirfenidone.	Expired/Abandoned	290751	10/06/2011	Cell Therapy and Technology S.A. de C. V.
United States	63/010,009	04/14/2020	Pirfenidone for Coronavirus Treatment	Pending			Cell Therapy and Technology S.A. de C. V.